Stress-induced suppression of pulsatile Luteinising hormone release in the female rat: role of vasopressin.
Insulin-induced hypoglycaemic (IIH) stress evokes the release of arginine vasopressin (AVP) and suppresses luteinising hormone (LH) pulses in a number of species, a phenomenon augmented by the presence of oestradiol (E2). The aim of this study was to test the hypothesis that AVP not only disrupts pulsatile LH secretion in the female rat, but specifically mediates the effect of IIH stress on suppressing LH release. The role of E2 in augmenting the disruptive effect of AVP on LH secretion was also addressed. Rats were ovariectomized (OVX) and fitted with intracerebroventricular (i.c.v. ) and intravenous (i.v.) cannulae. For experiments requiring comparisons of neuroendocrine responses in the presence and absence of E2, animals were implanted subcutaneously with E2 or oil-filled capsules respectively. AVP (5 microg) administered via the i.c.v. cannula suppressed LH secretion by decreasing LH pulse amplitude without affecting LH pulse frequency, an effect that was blocked by central administration of an AVP antagonist (25 microg). This inhibitory response was evident only in E2-replaced OVX rats, thus suggesting a sensitizing influence of the gonadal steroid. In the AVP-deficient Brattleboro rats, IIH stress did not interrupt pulsatile LH secretion as demonstrated in Long Evans and Wistar controls. While these data might suggest a pivotal role for AVP in stress-induced suppression of LH release, central administration of an AVP antagonist did not prevent the interruption of LH pulses in response to IIH stress. Furthermore, it would appear that AVP is not primarily involved in hypoglycaemic stress-induced suppression of pulsatile LH secretion since central administration of very high doses of AVP resulted in a suppression of LH pulse amplitude and not frequency, while hypoglycaemic stress caused an interruption of LH pulses.
Cates
P S
PS
Division of Anatomy, Cell and Human Biology, School of Biomedical Sciences, King's College London, London, UK.
Forsling
M L
ML
O'byrne
K T
KT
D000818:Animals; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D007003:Hypoglycemia / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D007004:Hypoglycemic Agents; D007328:Insulin; D007986:Luteinizing Hormone / Q000378:metabolism*; D010052:Ovariectomy; D011673:Pulsatile Flow; D051381:Rats; D011910:Rats, Brattleboro / Q000378:metabolism; D017208:Rats, Wistar; D013312:Stress, Physiological / Q000378:metabolism*; D014667:Vasopressins / Q000502:physiology*
D007004:Hypoglycemic Agents; D007328:Insulin; D014667:Vasopressins; D001127:Arginine Vasopressin; D004958:Estradiol; D007986:Luteinizing Hormone